Search - tctmd.com

Displaying 301 - 320 of 420

Sort: Relevancy | Date

Presentation TCT 2015

New Insights Into Neoatherosclerosis as a Frequent Common Denominator of DES Failure

Presenter: Robert A. Byrne, Stefan K. James, Renu Virmani

October 11, 2015

Presentation TCT 2015

Stent Thrombosis Update: Causes, Predictors, Implications, and Treatment

Presenter: Robert A. Byrne, Stefan K. James

October 11, 2015

Presentation TCT 2015

How Was This Patient Treated?

Presenter: Kevin J. Beatt, Craig R. Smith, Hemal Gada

October 11, 2015

Presentation TCT 2015

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? Yes, an Evidence-Based Position!

Presenter: Kevin J. Beatt, Craig R. Smith, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy!

Presenter: Kevin J. Beatt, Craig R. Smith, David J. Maron

October 11, 2015

Presentation TCT 2015

Case Presentation: Pretreatment A Patient With Class II Angina and Anterior Wall Ischemia

Presenter: Kevin J. Beatt, Craig R. Smith, Hemal Gada

October 11, 2015

Presentation TCT 2015

How the Case Was Treated

Presenter: Kevin J. Beatt, Craig R. Smith, Javier Escaned

October 11, 2015

Presentation TCT 2015

Case Presentation Pretreatment: MVD Disease With Intermediate SYNTAX Score: How Should This Patient Be Treated?

Presenter: Kevin J. Beatt, Craig R. Smith, Javier Escaned

October 11, 2015

Presentation TCT 2015

Assessment and Implications of Surgical Inoperability: Who Is at High Risk?

Presenter: Kevin J. Beatt, Craig R. Smith, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Functional Risk Scoring: Fame 3 and Beyond

Presenter: Kevin J. Beatt, Craig R. Smith, William F. Fearon

October 11, 2015

Presentation TCT 2015

Are Risk Scores Practical and Useful to Differentiate PCI vs CABG?

Presenter: Kevin J. Beatt, Craig R. Smith, Davide Capodanno

October 11, 2015

Presentation TCT 2015

The SYNTAX Score in Clinical Practice: Promise and Pitfalls

Presenter: Kevin J. Beatt, Craig R. Smith, Philippe Généreux

October 11, 2015

Presentation TCT 2015

Critical Analysis of Current Guidelines on Multivessel Revascularization: Are They Up to Date?

Presenter: Kevin J. Beatt, Craig R. Smith, Marie-Claude Morice

October 11, 2015

Presentation TCT 2015

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Presenter: John A. Bittl, E. Magnus Ohman, Marco Valgimigli

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study

Presenter: John A. Bittl, E. Magnus Ohman, James B. Hermiller Jr

October 11, 2015

Presentation TCT 2015

Featured Lecture: New DAPT Duration Recommendations

Presenter: John A. Bittl, E. Magnus Ohman

October 11, 2015

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Emmanouil S. Brilakis, Rajesh V Swaminathan

October 11, 2015

Advertisement

New Insights Into Neoatherosclerosis as a Frequent Common Denominator of DES Failure

Stent Thrombosis Update: Causes, Predictors, Implications, and Treatment

How Was This Patient Treated?

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? Yes, an Evidence-Based Position!

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy!

Case Presentation: Pretreatment A Patient With Class II Angina and Anterior Wall Ischemia

How the Case Was Treated

Case Presentation Pretreatment: MVD Disease With Intermediate SYNTAX Score: How Should This Patient Be Treated?

Assessment and Implications of Surgical Inoperability: Who Is at High Risk?

Functional Risk Scoring: Fame 3 and Beyond

Are Risk Scores Practical and Useful to Differentiate PCI vs CABG?

The SYNTAX Score in Clinical Practice: Promise and Pitfalls

Critical Analysis of Current Guidelines on Multivessel Revascularization: Are They Up to Date?

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study

Featured Lecture: New DAPT Duration Recommendations

Lessons From the TAXUS Liberté/Prasugrel Substudy

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content